Douglas Rovira, MD
Hematology & Oncology · Chicago, ILNPI 1598767733
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 9.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in IL, where the typical reported total is $2,365.
Across 83 payments — averaging $22.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$179
- Merck$163
- Takeda Pharmaceuticals U.S.A., Inc.$146
- E.r. Squibb & Sons, L.L.C.$111
- Jazz Pharmaceuticals Inc.$96
- AbbVie$79
- plus $1K from 34 others
Across 4 payments — averaging $22,930 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$88K
- Tesaro, Inc.$2K
- Amgen$846
- Bristol Myers Squibb$778
What the payments were for
- Food & beverage$1,84797%
- Education$613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $179 |
| Merck | 9 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $146 |
| E.r. Squibb & Sons, L.L.C. | 5 | $111 |
| Jazz Pharmaceuticals Inc. | 4 | $96 |
| AbbVie | 3 | $79 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Novartis | 4 | $67 |
| GSK | 3 | $67 |
| Bayer | 3 | $65 |
| Gilead | 3 | $60 |
| Genentech USA, Inc. | 3 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $57 |
| Boehringer Ingelheim | 2 | $54 |
| Incyte Corporation | 2 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Stemline Therapeutics Inc. | 1 | $35 |
| Genmab U.S., Inc. | 1 | $31 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $27 |
| Tersera Therapeutics LLC | 1 | $27 |
| Beone Medicines USA, Inc. | 1 | $27 |
| EMD Serono, Inc. | 1 | $26 |
| Pfizer | 1 | $25 |
| Clovis Oncology, Inc. | 1 | $25 |
| Blueprint Medicines Corporation | 1 | $25 |
| ADC Therapeutics America, Inc. | 1 | $24 |
| Fresenius Kabi USA, LLC | 1 | $24 |
| Sanofi | 1 | $22 |
| Sobi, Inc | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Amgen | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| EUSA Pharma (US) LLC | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Exelixis Inc. | 1 | $18 |
| Seagen Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $12 |
How this compares
$1,908 in reported general payments places this provider in the 45th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 15 | $178,086 |
| PromactaEltrombopag Olamine | 12 | $100,828 |
| Abiraterone Acetate | 16 | $59,783 |
| EliquisApixaban | 15 | $10,970 |
| Anastrozole | 58 | $683 |
| Dexamethasone | 32 | $585 |
| Hydroxyurea | 29 | $377 |
| Prochlorperazine Maleate | 37 | $332 |
| Ondansetron OdtOndansetron | 20 | $253 |
| Oxycodone Hcl | 14 | $219 |
| Prednisone | 25 | $165 |
| Ondansetron Hcl | 16 | $95 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $69 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $27 | $178,08615 claims |
| NovartisPromacta | $67 | $100,82812 claims |
| PfizerEliquis | $25 | $10,97015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Chicago
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Chih-Yi LiaoChicago$317K
- Rita NandaChicago$286K
- Shuo MaChicago$280K
- Santosh SarafChicago$275K
- Peter RiedellChicago$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.